This suggests that STAG2 mutations tend to be acquired at the MDS stage, and RAD21 and the other cohesin subunit mutations may be more likely acquired at the AML stage and lead to rapid leukemic transformation rather than a slower increase in blast count over time, as may be expected in MDS. This evidence concerns the gene RAD21 and acute myeloid leukemia.